Cidara Therapeutics, Inc.
CDTX
Hisse Senetlerindeki Sıralama
#3187
Cidara Therapeutics, Inc. is a biotechnology company specializing in the... Cidara Therapeutics, Inc. is a biotechnology company specializing in the creation, advancement, and commercialization of extended-duration anti-infective drugs. Their mission targets the prevention and treatment of infectious diseases and certain cancers within the U.S. Their primary therapeutic candidate, rezafungin acetate, is an innovative echinocandin antifungal designed to combat and avert severe fungal infections such as candidemia and invasive candidiasis, conditions known for their high fatality rates. Additionally, Cidara utilizes its Cloudbreak platform to engineer conjugated therapies aimed at preventing and treating influenza as well as various other viral illnesses, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and SARS-CoV-2, the pathogen behind COVID-19. Originally incorporated in 2012 as K2 Therapeutics, Inc., the company adopted its current name, Cidara Therapeutics, Inc., in July 2014. Its operations are headquartered in San Diego, California.
Hisse Fiyatı
$221.38
Son senkronizasyon: 2026-01-08
Piyasa Değeri
$5.61B
Değişim (1 gün)
0.00%
Değişim (1 yıl)
118.07%
Ülke
US
Ticaret Cidara Therapeutics, Inc. (CDTX)
Kategori
Healthcare
Cidara Therapeutics, Inc. (CDTX) için P/B oranı
October 2026 itibarıyla P/B oranı TTM: 8.15
Cidara Therapeutics, Inc. şirketinin en son mali raporları ve hisse fiyatına göre, mevcut P/B oranı (TTM) 8.15'dir. 2023 yılının sonunda şirketin P/B oranı -8.46 idi.
Cidara Therapeutics, Inc. için P/B oranı geçmişi 2012 - 2026 arası
Her yılın sonunda P/B oranı
| Yıl | P/B Oranı | Değiştir |
|---|---|---|
| 2026 (TTM) | 8.15 | 676.07% |
| 2024 | 1.05 | -112.36% |
| 2023 | -8.46 | -53.54% |
| 2022 | -18.20 | -689.60% |
| 2021 | 3.09 | -60.21% |
| 2020 | 7.76 | 155.31% |
| 2019 | 3.04 | 195.54% |
| 2018 | 1.03 | -48.39% |
| 2017 | 1.99 | 16.56% |
| 2016 | 1.71 | -24.85% |
| 2015 | 2.27 | 265.81% |
| 2014 | 0.62 | -116.78% |
| 2013 | -3.70 | -95.75% |
| 2012 | -87.22 | 0.00% |
Benzer şirketler veya rakipler için P/B oranı
| Şirket | P/B Oranı | P/B Oranı Farkı | Ülke |
|---|---|---|---|
| 6.251 | -23.29% |
US
|
|
| 13.2547 | 62.66% |
US
|
|
| 4.208 | -48.36% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -24.13% |
NL
|
